Journal Article > CommentaryFull Text
Lancet. 2024 April 29; Volume 403 (Issue 10439); 1825-1827.; DOI:10.1016/S0140-6736(24)00749-9
Coulborn RM, Danet C, Alsalhani A
Lancet. 2024 April 29; Volume 403 (Issue 10439); 1825-1827.; DOI:10.1016/S0140-6736(24)00749-9
Worldwide, more than 99% of the burden of measles infections and deaths affects populations in low-income and middle-income countries. Measles accounts for 3% of the global mortality of children younger than five years, constituting 90% of deaths from measles, and rubella is the main vaccine-preventable cause of birth defects. Vaccine coverage, both through routine immunisation and supplementary immunisation activities, remains below targets for measles elimination, with considerable heterogeneity between and within countries.